Search results for: 'Complex Drug'

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

More than 6,000 molecules are currently in clinical development across the pharmaceutical research and development (R&D) landscape, with more than 11,000 in the preclinical phase. The industry is witnessing the growth of small- to mid-segment pharma/biotech players making significant contributions to drug discovery and development pipelines. Across...

This study provides a comprehensive analysis of the contract research and manufacturing services (CRAMS) segment in India by focusing on drug discovery to pre-clinical toxicology, Active Pharmaceutical Ingredient (API), Formulations and Injectables. The study is based on detailed primary research, and includes an evaluation of the market size as we...

19 Apr 2017  |  Asia Pacific  |  Market Research

Global CRO Market, Forecast to 2021

The Global CRO Market to Reach $64.58 Billion by 2021

Infographics

×

The Global CRO Market, Forecast to 2021, presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market. It provides revenue forecasts for CROs globally by phase, therapeutic type and region. With the consolidation of the market as well as a higher cost and risk involved, the big companies are slowly shifting ...

Over the past 2 years the global pharmaceutical industry has been shifting its focus towards the emerging market such as India. The CRAMS segment in India is expected to be one of the biggest beneficiaries of this wave. This study presents a comprehensive study of the Indian contract research and manufacturing services market from drug discovery t...

This study carries Frost & Sullivan’s observation of bone mineral density solutions in select Asian Countries (Australia, South Korea, and China); the regulatory trends for the same have been covered, highlighting the following: • Product registration and regulatory approval process details in select Asian countries (such as the Therapeutic Goods A...

The Asia-Pacific (APAC) integrated facility management (IFM) market has experienced steady growth, primarily driven by developing economies. While mature markets have shown slower progress, the overall trend is positive. Strong regulatory support, particularly from the public sector, and a growing emphasis on energy efficiency have fueled IFM ad...

The healthcare expenditure in Australia in the previous financial year was AUD 170.4 billion, with 10.3% of the gross domestic product (GDP), thereby allowing the country’s healthcare spending to pass the 10% mark for the first time. Healthcare expenditure continues to rise; however, the rate of increase has been curbed in the last few years. At AU...